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Summary The accuracy of immunodetection by dual parameter flow cytometry (FCM), polymerase chain
reaction-mediated single strand conformation polymorphism (PCR-SSCP) and genomic sequencing to detect
p53 mutations were compared. Analysis by the last two techniques was restricted to exons 5 -8. Initially, 110
breast tumours were screened for p53 expression by FCM. Seventy (64%) of tumours were immunopositive.
Fifteen highly immunopositive and 15 completely immunonegative tumours were selected for further analysis
by PCR-SSCP and genomic sequencing. Eleven out of 15 immunopositive tumours were found to have
mutation by PCR-SSCP. Genomic sequencing confirmed the presence of mutation in 10 of these 11
immunopositive tumours. Therefore, four immunopositive tumours failed to show mutation by SSCP and five
by genomic sequencing. Of the 15 immunonegative tumours, one showed mutation by both PCR-SSCP and
genomic sequencing and one tumour has undergone deletion of the p53 gene. Overall, immunoreactivity
correlated with both PCR-SSCP and genomic sequencing in 80% of cases (24/30), and there was 96.5% (28/
29) concordance between PCR-SSCP and genomic sequencing. We conclude that there is good concordance
between mutations detected by PCR-SSCP and genomic sequencing, but immunochemical detection of p53
overexpression is not an absolute indicator of p53 gene mutation.
Keywords: p53 mutation; breast cancer; flow cytometry; polymerase chain reaction-single strand conformation
polymorphism; genomic sequencing; immunohistochemistry
Sporadic mutation of the p53 tumour-suppressor gene is the
single most common genetic alteration seen in human cancer
(Nigro et al., 1989). The most commonly used methods for
detection of these mutations are immunocytochemistry,
polymerase chain reaction-single-strand conformation poly-
morphism (PCR-SSCP) and genomic or cDNA sequencing.
Although sequencing is the most unambiguous method, it is
technically cumbersome. Therefore, both immunodetection
and PCR-SSCP have been widely used as alternative
methods. Since the majority of p53 missense mutations are
found clustered between exons 5 and 8 (Hollestein et al.,
1991), most investgators have restricted mutation analysis to
this region. Missense mutations of p53 have been reported to
prolong the half-life of the protein by altering its
conformation (Matleshewski et al., 1986; Gannon et al.,
1990; Milner and Medcalf, 1991). Consequently, immuno-
chemically detected p53 protein has generally been assumed
to indicate an underlying p53 gene mutation. Although this
has been validated in some of the earlier studies done on cell
lines (Iggo et al., 1990; Bartek et al., 1990a; Rodrigues et al.,
1990) and in human tumours (Davidoff et al., 1991; Thor et
al., 1992; Navone et al., 1993; Deng et al., 1994), there are
reports with varying degrees of discordance between the two
parameters (Allred et al., 1993; Kohler et al., 1993).
Wynford-Thomas (1992) and Hall and Lane (1994) have
also cautioned against the simplisitc interpretation of p53
immunocytochemistry on account of reports of immuno-
chemically detected wild-type p53 protein in the absence of
p53 gene mutation under a wide range of conditions (Hall et
al., 1993; Rasbridge et al., 1993; Lane, 1994). It was,
therefore, important to establish how closely p53 mutations
observed using PCR-SSCP and immunohistochemical
methods correlated with p53 gene mutations detected by
sequencing and with each other.
We report here a systematic comparative analysis of p53
mutations detected by immunofluorescence using dual
parameter flow cytometry, PCR-SSCP and genomic
sequencing using human breast cancer tissues. Our objective
was to look for the degree of concordance among the three
methods of detecting p53 mutation and to verify whether
immunochemical detection of p53 accumulation truly
indicates the presence of p53 mutation and, if so, to what
extent.
Materials and methods
Breast cancer tissues were collected immediately after surgery
and transported to the laboratory on ice. After separating the
fatty tissue, they were frozen at -80°C. The cell line, T-47D,
SW 480 and HL-60, were obtained from the National Facility
for Animal Tissue and Cell Culture, Pune, India. The first
two cell lines have been reported to contain p53 mutations,
while the third has a deletion of this gene. These were
routinely grown in plastic T-75 flasks or on coverslips in
RPMI/Dulbecco's modified Eagle medium (DMEM) supple-
mented with 10% fetal calf serum (FCS), penicillin (100
units ml-') and streptomycin (100 ,ug ml-1). Cultures were
maintained at 37°C in an atmosphere of 5% carbon dioxide.
Cells grown in flasks were harvested, fixed with 0.25% cold
paraformaldehyde (PFA) and used for flow cytometry. Cells
grown on coverslips were fixed in 1: 1 (v/v) acetone methanol
and used for immunocytochemistry.
Immunohistochemical localisation ofp53 protein
Specificity of PAb 1801 (Banks et al., 1986) and DO-7
(Dako) monoclonal antibodies to detect nuclear accumula-
tion of mutated p53 protein was checked by immunocyto-
chemistry on T-47D and SW 480 cells, and
immunohistochemically on paraffin-embedded breast tumour
tissues. Two negative controls were processed simultaneously.
In the first, sections were incubated with normal mouse
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serum diluted 1: 2000. In the second, a non-specific isotypic
control monoclonal antibody IgGI for CD4 was used. Cells
were considered immunopositive if a majority of cells showed
nuclear accumulation of p53 protein.
Flow cytometry for p53 expression and measurement of DNA
content
To prepare a single-cell suspension, human breast tumour
tissues were thawed, minced on ice and homogenised in
chilled phosphate-buffered saline (PBS). The homogenate was
filtered through a 35 pm mesh and washed repeatedly with
PBS to remove debris and fatty material. After taking cell
counts it was either used immediately or frozen at -20 'C. A
portion of the cell suspension was used for DNA extraction.
For flow cytometry, approximately two million cells were
fixed in 0.25% cold PFA at 4°C for 1 h and permeabilised
with 0.1% Triton x 100.
For immunofluorescence, the permeabilised cell pellets were
incubated for 5 min at room temperature with 1 ml PBS
supplemented with 2% FCS and 0.1% sodium azide. To the
control pellet was added a non-specific isotypic control
antibody IgGl for CD4 at a concentration of 100 pg ml-'
per one million cells, and to the other was added the
monoclonal antibodies PAb 1801 or DO-7 at the same
concentration as above at room temperature for 1 h. After
repeated washingwith PBS, the pellets were incubated in FITC-
conjugated rabbit anti-mouse IgG at 1: 50 dilution for 30 min
at room temperature in the dark. Cells were further stained for
DNA with 50 pug ml-
1 propidium iodide (PI). Aggregates, if
formed, were dissociated through a 28-gaugle needle and the
samples were analysed within 20-30 min of exposure to PI.
The sensitivity of the immunofluorescence assay was
determined using the same two cell lines which had been
used for the immunocytochemical assay. Both T-47D and SW
480 served as positive controls of mutated p53 protein
expression, while HL-60 (which has a deleted p53 gene) was
used as a negative control. These cell lines were run in
parallel to monitor the performance of the instrument each
time a breast tumour tissue was assayed for p53 expression.
A total of 110 breast tumours were analysed.
Samples were analysed using an Epics profile-I multi-
parameter flow cytometer (Coulter Electronics, Florida,
USA), equipped with an argon-ion laser operating at
15 m W with 488 nm excitation line. Green (FITC) and red
fluorescence (PI) corresponding to p53 expression and DNA
content, respectively, were measured simultaneously and were
separated optically by using a 550 nm dichroic filter. In
addition, the green and red photomultiplier tubes were
guarded by 525 bandpass and 610 longpass filters respec-
tively. No spectral overlap between these fluorescence signals
was observed. Doublet discrimination was performed by
collecting peak vs integral signals.
p53 expression was evaluated by analysing logarithmic
fluorescence signals using Epics Elite cytometry Immuno-4
software package (Phoenix Flow Systems, San Diego, USA).
The presence of5% p53-positive cells was used as a cut-offlevel
to distinguish immunopositive from immunonegative tumours.
Design ofp53 gene-specific primers
On the basis of published sequences (Gene Bank-EMBL
database, accession number X54156) and previous reports
(Toguchida et al., 1992), primers specific to exons 5, 6, 7 and
8 from the intron -exon junctions were designed using oligos-
4 software. Two overlapping primer pairs were chosen for
exon 5. The primer pairs were selected such that they would
amplify fragments that provide satisfactory resolution for
detection of single base changes by SSCP.
PCR-SSCP analysis
A portion of the single cell suspension prepared from human
breast tissues for flow cytometry and normal human
peripheral blood lymphocytes (NHPBLs) were used to
extract high molecular weight DNA (Maniatis et al., 1982).
PCR fragments corresponding to exons 5-8 of the p53
gene were generated from 50-100 ng genomic DNA in a
100 pl reaction mixture containing 10 pmol of each primer,
150 pUM of each dNTP, 1.0 U Taq polymerase and
1 x reaction buffer. PCR was carried out for 30 cycles on a
programmable thermal cycler with denaturation at 95°C for
1 min, annealing at 52-60°C for 1 min, and extension at
72°C for 2 min. The PCR products were analysed by agarose
gel electrophoresis. If additional bands were present, the
fragment of interest was cut out, DNA eluted from low-
melting agarose (LMA) gel and used as a template for a
second PCR reaction.
PCR-SSCP protocol was essentially the same as reported
by Orita et al. (1989) with minor modifications. The second
PCR for SSCP anlaysis was performed for 15 cycles under
the same conditions as used for the first PCR except that
0.5 pmol of 5' end-labelled primers were used in a 10 pl
reaction. Further, 1.0 pl of the labelled PCR product was
diluted into 10 ,ul of sequencing stop solution with 10 mM
sodium hydroxide and was heated to 95°C for 5 min. PCR
products amplified from normal peripheral blood DNA were
used as controls for PCR-SSCP analysis. For optimal
resolution of the SSCP pattern of each exon, the run time
was varied between 18 and 24 h. The samples were run at
3 W on 6% non-denaturing polyacrylamide gel with 10%
glycerol at room temperature, or on MDE (AT Biochem,
USA) gel as per the manufacturer's instructions.
Genomic sequencing ofexons 5-8
PCR products corresponding to exons 5 and 6 were
sequenced directly. Initially, the products were treated with
exonuclease-I and shrimp alkaline phosphatase to remove
the unused primers and dNTPs. The double stranded
templates were then denatured in a thermal cycler in the
presence of excess of one of the exon-specific primers. These
were then snap frozen to allow rapid annealing of the
primer to the template. To ensure terminations close to the
primer, 3-5 pmol of the template was extended with 10-15-
fold diluted dNTPs using PCR sequenase (USB, USA).
Addition of Mn2" ions was found to improve terminations
in the first 200 bp region. However, PCR products
corresponding to exons 7 and 8 repeatedly gave rise to
non-specific terminations resulting in high background.
These products were therefore cloned into pMOS(Blue)T
cloning vector (Amersham) for sequencing. The single
stranded phagmids rescued with helper phage MI3KO7
were sequenced using 0.5-1.0 pmol of both T-7 and exon-
specific 5'- primer in separate reactions with sequenase V.2
(USB, USA). p53 exons cloned from normal peripheral
blood DNA were used as control templates for sequencing.
The sequencing reactions were run on a 6% polyacryla-
mide 7 M urea gel which was fixed in acetic acid, dried and
exposed to Fuji xomat X-ray films for 18-24 h.
Results
Detection ofp53 overexpression usingflow cytometry
Immunocytochemical analysis of the cell lines and breast
tumour tissues clearly indicated that the antibodies PAb 1801
and DO-7 specifically recognised nuclear accumulation of
mutated p53 protein (Figure 1). Similarly, the flow cytometric
immuno-4 analysis of the three test cell lines confirmed the
sensitivty of the immunofluorescence assay in which the
percentage of cells overexpressing p53 protein was found to
vary according to the corresponding genetic abnormality.
Thus, both T-47D and SW 480 with known mutations in
exon 6 and 9 respectively, had 80-90% of cells over-
expressing the protein, whereas only 0.3% of HL-60 cells
with a deleted p53 gene were found to express the protein
(Figure 2). In addition, the specificity of the assay could bep53 mutations in breast cancer
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Figure 1 Nuclear accumluation ofp53 in (a) SW480 cells stained with monoclonal antibody PAbl801 (lOpugml-1); (b) SW480 cells
stained with non-specific antibody IgGl against CD4 (10jugml-'); (c) paraffin-embedded breast tumour stained with PAbl8O1
(20ygml-1); (d) paraffin-embedded breast tumour stained with non-specific antibody IgGl against CD4 (20/pgml-'). All
photomicrographs were taken at x 400 magnification. (e) is a lower power (100 x ) H and E section of the tumour specimen shown
in c and d under magnification.
increased by gating the immunofluorescence events on the
basis of their DNA profile, thereby reducing the background
fluorescence to a minimum. As expected p53 specific
immunofluorescence could be seen confined to cells not only
in GI and S, but also in G2/M phases of the cell cycle owing
to stabilisation of the mutant protein.
A total of 110 breast tumours were analysed for p53
expression. Forty (36%) tumours were found to have less
than 5% p53-positive cells and were classified as immunone-
gative. Seventy (64%) tumours had more than 5% p53-
positive cells and were considered immunopositive. Of these,
15 tumours had more than 15% p53-positive cells. These
were classified as highly immunopositive.
PCR- SSCP analysis ofp53 mutations in exons 5-8
To avoid ambiguity of results, the 15 highly immunoposi-
tive tumours and 15 completely immunonegative tumours
were analysed for p53 mutations at the genomic level by
PCR -SSCP. We excluded tumours showing moderate or
cp53 maSons in breas cancer
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low level expression of p53 because of possible inisinterpre-
tation of results anrsing from a dilution effect owing to the
presence of a large number of normal cells in such tumours.
The sensitivity of PCR-SSCP to resolve single base
changes on non-denaturing polyacrylamide gel (PAGE)
was checked with p53 exon 6 amplified from T-47D cell
line known to carry a mutation in exon 6. Normal
peripheral blood DNA amplified p53 exon 6 was run as
the wild-type control. Mutation was identified by the
presence of aberrantly migrating band(s) (Figure 3).
Although the exon 6 mutation of T47D could be resolved
on PAGE, none of the breast tumours showed mobility
shift for exon 6 on PAGE. These findings prompted us to
try the mutation detection and enhancement (MDE) gel.
which has been reported to enhance resolution of SSCP
patterns, particularly of exon 6 (Soto and Sukumar, 1992).
Two out of 15 tumours showed mobility shift under these
conditions (Figure 3).
Overall, PCR-SSCP detected mutations in 40% (12 30)
carcinomas. Eleven of these 12 mutations were in
immunopositive tumours and one in inmunonegative
tumour. The distribution of these mutations was six in
exon 5, two in exon 6, three in exon 7 and one in exon 8
(Figures 3 and 4). b
Fgure 2 Immuno4 analysis of the control cell lines (a) SW480
and (b) HL-60. by FCM. The program performs statistical
analysis on two single parameter immunofluorescenc histograms
and normalises and overlays the control histogram on the test
histogram in order to match best the analysis region. It then
substracts the control histogram from the test histogram on
channel-to-channel basis. The percentage positive fraction is
calculated from the sum of differences for all channels.
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Genomic sequencing of exons 5-8
The p53 coding region was sequenced across exons 5-8 in all
the 30 tumours selected for genomic analysis. Eleven tumours
out of 30 (36.6%) were found to be mutated on sequencing.
These mutations were present in all four exons analysed
(Table I). Exon 5 showed mutation in five tumours, exon 6 in
two, exon 7 in three and exon 8 in one tumour. The majority
of these mutations were base substitution mutations (Figure
5). However, one tumour in exon 7 showed a frameshift
mutation (Figure 5) and one immunonegative tumour had
deletion of the p53 gene. The latter, therefore, could not be
used for PCR-SSCP and sequencing. All the rest had wild-
type sequence.
Correlation between immunochemical detection ofp53, PCR-
SSCP andp53 gene mutation
Eleven out of 15 immunopositive tumours were found to
have mutation by PCR-SSCP. Genomic sequencing con-
firmed the presence of mutation in ten of these 11 tumours.
Thus, one immunopositive tumour that did show mutation in
exon 5 by SSCP, however, failed to show mutation on
sequencing. Since exon 5 had been amplified in two
overlapping fragments, it is unlikely that we would have
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Fgre 3 Electrophoretic pattern of p53 exon 6 DNA on SSCP analysis. Numbers represent breast tumours given in Table I. For
details. refer to the Materials and methods and results sections.
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Figure 4 Electrophoretic pattern of p53 exon 5, exon 7 and exon 8 DNA amplified from human breast tumours (BTs) and normal
human peripheral blood lymphocyte (NHPBL). BT-2, BT-3 and BT-4 show mobility shifts for exon 5. All the three-tumours (BT-1,
BT-6 and BT-8) show mobility shift for exon 7, whereas only BT-l1 shows mobility shift for exon 8. Numbers represent breast
tumours given in Table I. For details, refer to the Materials and results sections.
Table I Correlation between immoreactivity, mutation by PCR-
SSCP and genomic sequencing of p53 gene in breast tumours
Immuno
Breast (+) SSCP Base Codon
tumour cells (%) status change change
Immunopositive
BT-1 23.4 Ex-7 Deletion of T Frameshift
at codon 241
BT-2 26.2 Ex-5 A-*T CAT-+CTT
BT-3 31.4 Ex-5 A-,T CAC-+CTC
BT-4 30.3 Ex-5 A-+T GAG-+GTG
BT-5 18.0 ND ND
BT-6 30.2 Ex-7 C-)A ATC-+ATA
BT-7 30.9 Ex-6 C--G CCC--CCG
BT-8 40.3 Ex-7 A-+C AAC-+CAC
BT-9 34.8 Ex-6 G-+C TTG-TTC
BT-10 17.3 Ex-5 C-A CAG-+AAG
BT-11 21.7 Ex-8 T-+G GTG--GGG
BT-12 31.7 Ex-5 No mutation
BT-13 30.0 ND ND
BT-14 16.3 ND ND
BT-15 14.8 ND ND
Immunonegative
BT-16 4.6 ND ND
BT-17 0.7 ND ND
BT-18 0.3 ND ND
BT-19 0.8 EX-5 3-bp deletion TCA-+TCG
and codon
change CAGACG
BT-20 1.8 ND ND
BT-21 2.5 ND ND
BT-22 1.0 ND ND
BT-23 0.3 NTD ND
BT-24 1.9 ND ND
BT-25 3.7 ND ND
BT-26 2.4 ND ND
BT-27 0.3 Deletion
BT-28 0.6 ND ND
BT-29 1.3 ND ND
BT-30 2.5 ND ND
ND, not detected.
missed the mutation. Four immunopositive tumours failed to
show mutation by both PCR-SSCP and genomic sequen-
cing. Of the 15 immunonegative tumours, one tumour
actually harboured a 3 bp deletion and change of codon at
two consecutive positions. Additionally, one immunonegative
tumour had undergone deletion of at least exons 5-8 of the
p53 gene. Overall, immunoreactivity correlated with both
PCR-SSCP and genomic sequencing in 80% of cases (24/
30), whereas there was 96.5% concordance between PCR-
SSCP and genomic sequencing.
Discussion
Several assays have been used to analyse the presence of p53
mutations in human cancer, of which immunodetection of
p53 protein and PCR-SSCP are the most-frequently used
methods. Both the methods are limited by their vulnerability
to experimental conditions, resulting in difficult interpretation
of the results. We have, therefore, compared systematically
the immunochemical method with PCR-SSCP and genomic
sequencing for p53 mutations in human breast tumours.
Initially, 110 breast tumour were screened for p53 expression
by dual parameter flow cytometry. A comparative analysis
was then carried out in a subset of 15 highly immunopositive
tumours and 15 completely immunonegative tumours. Dual
parameter FCM analysis was preferred over immunocyto-
chemistry for the reasons given below.
The specificity of the antibodies PAb 1801 and DO-7 to
detect nuclear accumulation of p53 was confirmed by
immunocytochemistry in cultured cell lines and by immuno-
histochemistry on formalin-fixed paraffin-embedded human
breast tumour tissues. p53 expression was found confined to
neoplastic epithelial areas, specifically recognising nuclear
accumulation of p53 protein. It was consistent with the
findings of Bartek et al. (1990b). However, it was observed
that cultured cells without formalin fixation produced better
staining patterns. Hence, we analysed p53 expression by dual
parameter flow cytometry, which involved only mild fixation
in paraformaldehyde. Moreover, the flow cytometric im-
munofluorescence assay used was found to be quantitative
and highly specific as it monitors p53 expression and its
DNA content simultaneously, thereby minimising back-
ground fluorescence. It also enabled visual confirmation of
GI -S phase-specific p53 expression.
Sixty-four per cent of tumours were found to be
immunopositive by the flow cytometric assay as against
20-57% reported in earlier studies (Cattriotie et al., 1988;
Bartek et al., 1990; Davidoff et al., 1991; Deng et al., 1994).
Several factors may have been responsible for the higher
percentage of immunopositive tumours reported here. Firstly,
the antibodies may recognise the epitopes of p53 more
efficiently in its natural conformation under the conditions
that we used. Secondly, in contrast to the earlier definitions
of immunopositivity, such as: 'the presence of 20%
immunopositive cells' (Isola et al., 1992) or 'uniform p53p53 mwtatorns i breast cancer Poo G Chakravarty et al
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Figure 5 Genomic sequencing of exons 5-8 of the p53 gene in
human breast tumours. Each sequence is shown 5' (bottom) to 3'
(top). Sequences are show-n for BT-1. BT-6 (b and c) showing
mutation in exon 7 and BT-3 (a) showing mutation in exon 5.
Numbers refer to the breast tumours given in Table I.
staining in all the ceHls (DaVidoff et al.. 1991). we have uesd
the presence of 5%o p53-positive cells as a cut-off to
distinguish immunopositive from immunonegative tumours.
Immunoreactivity correlated with p53 mutations detected
by SSCP and sequencing in 80% (24 30) cases. Four out of 15
immunopositive tumours did not show mutation. Contrariwise.
1 15 immunonegative tumours were found to have mutation by
SSCP and sequencing. One tumour had a deleted p53 gene. The
four immunopositive tumours that failed to show mutation had
15%. 16%. 18% and 30% p53-positive cells respectively. It
may be argued that mutations were diluted beyond the
detection limit of SSCP technique and. therefore. remained
undetected in the first three of these tumours. or that the
threshold of immunopositivity chosen by us (>15%) is still
within the range plausibly caused by variable induction ofwild-
type p53 in response to DNA damage genome instability. But
the lack of mutation in the immunopositive tumour with as
high as 30% p53-positive cells, indicates that these tumours
may be expressing the wild-type protein. This was further
confirmed by sequencing. The immunopositive phenotype may
have been due to its stabilisation on its interaction with cellular
proteins such as hsp-70 or some unknown viral proteins. Moll
et al. (1995) have suggested that cytoplasmic sequestration of
wild-type p53 may be another mechanism for its inactivation.
although this issue cannot be resolved in our study. since we
determined p53 expression by flow cytometry and not by
immunohistochemistry. Of course. the possibility of these
tumours harbouring a mutation outside the consenred exons
5-8 cannot, however, be ruled out.
Point missense mutations were observed in the sequence-
specific DNA binding domain of p53 in 11 tumours. They
occured at highly conserved residues (codons 143. 166. 167.
168. 171. 179. 206. 219. 238. 241. 250 and 271). As p53 is a
DNA binding protein, mutation at codon 179 may have
drastic consequences as the amino acid histidine at this
position is involved in zinc coordination and DNA binding
(Cho et al.. 1994). Similarly, all the other mutations found
also lie in the L, loop of the fl-sandwich (163-195 residues).
which is involved in maintaining the tetrahedral geometry of
zinc. Codon 143 is directly involved in establishing DNA
contact (Cho et al., 1994). It. therefore. might be clinically
important to determine the difference in behaviour of
tumours between those having mutations at these function-
ally critical residues and those with mutations at other sites.
The largest number of mutations were found in exon 5 in
agreement with others (Osborne et al.. 1991: Deng et al.. 1994).
Most of these mutations were transversions. where purine and
pyrimidine residues were interchanged. But. as opposed to a
higher frequency (71%) ofG . C transversions found by Deng
et al. (1994). more A--T transversions (60%) were observed in
our study. Interestingly, one tumour which was immunonega-
tive and had shown mutation in exon 5 by SSCP on genomic
sequencing was found to have undergone a 3 bp deletion and
change ofcodons at two consecutive positions. The mutations
might have altered the protein conformation such that the
antibody no longer recoginsed the protein.
Deletion ofp53 is a relatively rare event (8.10%) (for review
see Levine er al.. 1994). In the present study. one out ofthe 30
tumours was found to have undergone deletion at least within
the conserved exons 5-8. None of these exons could be
amplified from this sample. Yet when DQ-. locus-specific
primers were used to check if other loci from the sample could
be amplified. a DNA fragment specific to that locus was
invariably obtained. The deletion of the p53 gene may be
responsible for the immunonegative phenotype ofthis tumour.
In conclusion, the study indicates that there is 80%
concordance among the three methods to detect p53
mutation. PCR -SSCP and genomic sequencing correlated
with each other in 96.5% of cases. Immunochemical
detection of p53 was, therefore. not an absolute indicator
of p53 gene mutation. Since it is the genomic mutation of p53
which confers growth advantage to the affected cell. the
ultimate aim of any p53 assay should be to detect a genomic
defect. Detection of overexpression of p53 protein alone (in
the absence of p53 mutation) may be misleading. as
stabilisation of p53 may be a transient phenomenon and
can revert to normality with time.
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